All Fulcrum Publications

June 24, 2024

Losmapimod, a p38α/βMAPK inhibitor for the Potential Treatment of Patients with FSHD

Jeff Jacobs, PhD

June 15, 2024

An open-label pilot study of losmapimod to evaluate the safety, tolerability, and changes in biomarker and clinical outcome assessments in participants with facioscapulohumeral muscular dystrophy type 1

Joost Kools, Nicol Voermans, John G. Jiang, Olga Mitelman, Michelle L. Mellion, Vivekananda Ramana, Baziel G.M. van Engelen

June 14, 2024

Facioscapulohumeral Muscular Dystrophy (FSHD) Disease Progression and Losmapimod Efficacy Assessed by Reachable Workspace in Both Arms

Joost Kools, MD

June 14, 2024

Interim Results of a Phase 1b Study (PIONEER) of an Oral HbF Inducer, Pociredir, in Sickle Cell Disease

Kenneth Rivlin, MD, PhD; Jae Ahn, PhD; William Engelman, MD; Billy Stuart, PhD; Caterina Minniti, MD

June 13, 2024

Reliability and Validity of Reachable Workspace Total Score with Wrist Weights in Facioscapulohumeral Muscular Dystrophy

Lena Hubig, Adi Eldar-Lissai, Siu Hing Lo, John Jiang, Sarah Acaster, David Cella

June 13, 2024

Safety and Tolerability of Losmapimod for the Treatment of FSHD

Mihaela Levitchi Benea, MD; Marie-Helene Jouvin, MD; Vivekananda Ramana, MD; John Jiang, PhD

June 13, 2024

Characteristics of the Enrolled Population in the Phase 3 REACH Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)

Nicol C Voermans, MD, PhD; Doris G Leung, MD, PhD; Marie-Helene Jouvin, MD; John Jiang, PhD

April 15, 2024

Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial

Rabi Tawil MD, Prof Kathryn R Wagner MD, Johanna I Hamel MD, Doris G Leung MD, Jeffrey M Statland MD, Prof Leo H Wang MD, Angela Genge MD, Prof Sabrina Sacconi MD, Prof Hanns Lochmüller MD, David Reyes-Leiva MD, Prof Jordi Diaz-Manera MD, Jorge Alonso-Perez MD, Nuria Muelas PhD, Juan J Vilchez MD, Alan Pestronk MD, Summer Gibson MD, Prof Namita A Goyal MD, Prof Lawrence J Hayward MD, Nicholas Johnson MD, Samantha LoRusso MD, John G Jiang PhD

March 3, 2024

Facioscapulohumeral Muscular Dystrophy (FSHD) Disease Progression and Losmapimod Efficacy Assessed by Reachable Workspace in Both Arms

Rabi Tawil, MD, University of Rochester Medical Center, Joost Kools, MD, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Marie-Helene Jouvin, MD, Fulcrum Therapeutics, John Jiang, PhD, Fulcrum Therapeutics

March 3, 2024

Losmapimod, a p38 Small Molecule Inhibitor, Selectively Inhibits the DUX4 Program Without Negatively Impacting Myogenesis in FSHD

Genevieve Wilson, Erin Valentine, Joseph Maglio, Anthony Accorsi, Alejandro Rojas and Jeff Jacobs